- Home
- KNSA vs MNKD Comparison
KNSA vs MNKD Comparison
Compare KNSA & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- MNKD
- Stock Information
- Founded
- KNSA 2015
- MNKD 1991
- Country
- KNSA United Kingdom
- MNKD United States
- Employees
- KNSA N/A
- MNKD N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- KNSA Health Care
- MNKD Health Care
- Exchange
- KNSA Nasdaq
- MNKD Nasdaq
- Market Cap
- KNSA 1.7B
- MNKD 1.8B
- IPO Year
- KNSA 2018
- MNKD 2004
- Fundamental
- Price
- KNSA $20.59
- MNKD $6.85
- Analyst Decision
- KNSA Strong Buy
- MNKD Strong Buy
- Analyst Count
- KNSA 5
- MNKD 7
- Target Price
- KNSA $36.60
- MNKD $8.71
- AVG Volume (30 Days)
- KNSA 290.2K
- MNKD 3.3M
- Earning Date
- KNSA 10-29-2024
- MNKD 11-07-2024
- Dividend Yield
- KNSA N/A
- MNKD N/A
- EPS Growth
- KNSA N/A
- MNKD N/A
- EPS
- KNSA N/A
- MNKD 0.08
- Revenue
- KNSA $384,098,000.00
- MNKD $267,200,000.00
- Revenue This Year
- KNSA $60.05
- MNKD $45.36
- Revenue Next Year
- KNSA $36.32
- MNKD $16.99
- P/E Ratio
- KNSA N/A
- MNKD $86.40
- Revenue Growth
- KNSA 54.41
- MNKD 51.35
- 52 Week Low
- KNSA $16.56
- MNKD $3.17
- 52 Week High
- KNSA $28.15
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- KNSA 40.95
- MNKD 56.28
- Support Level
- KNSA $19.97
- MNKD $5.81
- Resistance Level
- KNSA $20.85
- MNKD $6.42
- Average True Range (ATR)
- KNSA 0.69
- MNKD 0.32
- MACD
- KNSA 0.03
- MNKD -0.01
- Stochastic Oscillator
- KNSA 35.61
- MNKD 82.54
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.